At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
PTX-022drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations
In Brief
A Phase 2 clinical trial evaluating PTX-022 for Microcystic Lymphatic Malformation. Completed, enrolled 12 participants across 7 sites.
Detailed Summary
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrocystic Lymphatic Malformation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartJan 2022
Primary CompletionNov 2022
Study CompletionDec 2022
TodayJul 2026
First PostedSep 20, 2021
Enrollment StartJan 13, 2022
Primary CompletionNov 15, 2022
Study CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.8 years ago
Interventions
PTX-022drug
Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations